Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688554 | 0.74 | — | — | |
| SCHEMBL7688553 | 0.74 | — | — | |
| SCHEMBL9586094 | 0.68 | CRBN (0.32) | CRBN | |
| SCHEMBL22869208 | 0.65 | ADRA2A (0.33) | CRBN | |
| SCHEMBL12660855 | 0.65 | — | — | |
| SCHEMBL3145577 | 0.64 | MAPK1 (0.31) | CRBN | |
| SCHEMBL8931418 | 0.64 | ALDH1A1 (0.34) | CRBN | |
| SCHEMBL14592897 | 0.64 | ALDH1A1 (0.34) | CRBN | |
| SCHEMBL14592820 | 0.64 | ALDH1A1 (0.34) | CRBN | |
| SCHEMBL24109071 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2021000785-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF JANUS KINASE 1 | 深圳美莹基因科技有限公司 | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | CRBN 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.